DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy
Viaskin Peanut is the Company’s lead product candidate designed to potentially reduce the risk of life-threatening allergic reactions due to accidental exposure to peanuts. A non-invasive, once-daily, epicutaneous